PH94B was wnxiety to placebo in decreasing mean peak levels generralized symptoms of social anxiety, as measured by subject-reported subjective units of distress SUDs. Less likely to cause metabolic effects. No active metabolite.

Video

When Should an Anxiety Disorder Patient Take Medication? Our anxieyt Antidepressant for generalized anxiety disorder of Mayo Qnxiety experts can help you with your generalized Antideptessant disorder-related health concerns Start Here. Treatment decisions Gut health and gluten intolerance based on how significantly generalized anxiety Antidepressant for generalized anxiety disorder is affecting your ability Atnidepressant function in your daily life. The two main treatments for generalized anxiety disorder are psychotherapy and medications. You may benefit most from a combination of the two. It may take some trial and error to discover which treatments work best for you. Also known as talk therapy or psychological counseling, psychotherapy involves working with a therapist to reduce your anxiety symptoms. Cognitive behavioral therapy is the most effective form of psychotherapy for generalized anxiety disorder.

Antidepressant for generalized anxiety disorder -

An analog of riluzole, troriluzole BHV , underwent a Phase III trial in GAD which has been completed although the results have not been published NCT There are several animal studies of AMPA modulators, including PEPA, primarily in fear extinction models of anxiety, showing positive anxiolytic effects One AMPA modulator, Org , has been studied for MDD To date, however, there are no known studies in the pipeline for AMPA modulators for anxiety disorders.

D-cycloserine DCS , an NMDA partial agonist, is among the most widely studied glutamatergic agents in anxiety D-cycloserine is unique in that research to date has focused on the effects of DCS on anxiety in the context of psychotherapy or fear learning.

In animal and human studies, DCS has been shown to facilitate fear extinction D-cycloserine has been studied for augmentation of psychotherapy in PD, SAD, and specific phobias. A Cochrane review reported no difference between DCS and placebo in augmentation of cognitive and behavioral therapies in anxiety and related disorders at study endpoint or follow up, in both children and adolescents A meta-analysis of DCS in anxiety disorders found a small difference between DCS and placebo post-treatment but minimal gains on follow-up treatments Subsequent studies of DCS augmentation in PD have been mixed , In SAD, despite earlier studies showing promise for the use of DCS augmentation of exposure therapy — , there have been far less encouraging findings in subsequent studies , — Studies of DCS in SP, including acrophobia and spider phobia, have yielded inconsistent but mostly negative findings for DCS compared to placebo — There are no active clinical trials of DCS augmentation in PD, GAD, SAD, or SP.

On balance, while initial studies of DCS showed promise for use in augmentation of psychotherapies, subsequent larger-scale studies have been disappointing. Memantine, an NMDA receptor antagonist FDA-approved for the treatment of Alzheimer dementia, moderate-severe, was tested previously in preclinical studies as a potential antidepressant One study reported minimal improvement in seven patients with GAD, while 10 participants with OCD experienced modest benefit There are no known active studies of memantine for anxiety disorders.

Finally, nitrous oxide N 2 O , an inhaled anesthetic most often used in dental procedures, is a NMDA receptor antagonist Nitrous oxide can be used recreationally and has been associated with potential neurologic and psychiatric adverse effects There also has been some study of N 2 O for the treatment of alcohol withdrawal and a proof-of-concept study in MDD Although there is literature on using N 2 O for the treatment of dental phobia and other procedure-related anxiety , there is, to date, no known past or current study of N 2 O as a pharmacologic treatment of PD, GAD, or SAD.

Given how efficacious benzodiazepines GABA-A agonists are for the treatment of anxiety disorders, and how there may be potential benefits with pregabalin and gabapentin, there has been an effort to find novel GABAergic anxiolytic agents. To date, however, several GABA-A receptor subtype agonists have either failed to reach market due to lack of efficacy or poor tolerability 89 , AZD, a GABA-A alpha modulator, failed to separate from placebo in a Phase 2 comparative trial with placebo and alprazolam for GAD NCT PF, a GABA-A positive allosteric modulator, tested at two doses, failed to separate from placebo as an adjunctive treatment in patients with GAD On an encouraging note, BNC IW , an α7 nicotinic acetylcholine receptor—negative allosteric modulator which also modulates the GABA receptor, was reported to result in reduced amygdalar activation to fearful faces compared to placebo and comparably to lorazepam, in patients with GAD Although it is unknown how many GABA modulators are being studied in anxiety, preclinical research suggests that several agents may be in the pipeline For instance, SAGE is a GABA-A positive allosteric modulator that is under Phase III study for MDD and postpartum depression and is being explored for treatment of GAD , Neuropeptides are small proteins that work as neuronal signaling molecules and are involved in an array of brain functions such as analgesia, reward systems, social behaviors, learning, and memory.

In addition, specific neuropeptides such as oxytocin, substance P, neuropeptide Y NPY , arginine vasopressin AVP , and cholecystokinin CCK play significant roles in modulating fear and anxiety.

Oxytocin is a neuropeptide involved in attachment and pro-social behaviors. Due to its poor absorption in the digestive tract, oxytocin must be administered either intravenously, intranasally or sublingually, where it is well-tolerated with no known serious adverse effects Studies have shown that in healthy adults, oxytocin has positive effects on emotion modulation , and that low oxytocin has been associated with high anxiety Animal studies suggest that oxytocin has anxiolytic effects and human research suggests that oxytocin may increase anxiety acutely.

For example, a double-blind, placebo-controlled study of intranasal oxytocin on single-session exposure-based psychotherapy for arachnophobia found that oxytocin impaired treatment response compared to placebo Overall, however, oxytocin may have overall positive effects on anxiety depending on the frequency and context of administration Research on oxytocin for the treatment of anxiety disorders has been focused on SAD , , with studies reporting increasing amygdalar-prefrontal activity in response to emotional faces , and enhancing prosocial behaviors Although there is a large body of research on the use of oxytocin for augmentation of antipsychotics in schizophrenia , several of these trials have been called into question due to study design and sample size and there has been controversy about whether oxytocin can be absorbed into the brain with intranasal administration or if peripheral levels reflect central activity Currently, there is one known study evaluating intranasal oxytocin in patients suffering from acute anxiety and depression during psychiatric hospitalization NCT Substance P is one of the major neuropeptides found in the nervous system Given its abundance in the fear center of the brain, Substance P and its neurokinin receptor system have been a great topic of interest in anxiety disorder research Despite ample research interest, several trials have failed to demonstrate the efficacy of Substance P in reducing symptoms of anxiety disorders , , which has led to a decrease in pharmaceutical studies A recent study conducted by Frick et al.

This finding highlights the need for further research on utilizing NK1 receptor antagonists for the treatment of some anxiety disorders.

Currently, there are not any ongoing clinical studies that evaluate the use of Substance P for the treatment of anxiety disorders. Neuropeptide Y is one of the most abundant neuropeptides in the brain and numerous reports have found that NPY is critical for the stress adaptation process In humans, NPY has been closely linked to trauma.

Most recently, a small RCT of intranasally administered NPY in patients with MDD showed potential benefit for depression A study conducted by Sayed et al. found that intranasally administered NPY was associated with greater treatment response and improvement in anxiety ratings when compared to placebo in individuals with PTSD This finding encourages future research that studies the safety and efficacy of NPY as an anxiolytic treatment.

There are however no active trials of NPY in GAD, PD, or SAD. Arginine Vasopressin AVP has been shown in animal models to be related to anxiety responses and vasopressin V1a and V1b receptor antagonists may have anxiolytic properties , Few human studies of V1 antagonists have been published.

Griebel et al. Conversely, studies conducted by Fabio et al. There are currently no known clinical trials studying V1a antagonists in the treatment of anxiety disorders.

Cholecystokinin CCK is a peptide which helps regulate gastric secretions and motility and biliary function in the gastrointestinal system; in the brain, CCK is found in the brain's fear network e.

Current research surrounding CCK is complex in that CCK agonists are panicogenic, but CCK-2 antagonists fail to alleviate human anxiety , leaving many unanswered questions regarding the role of CCK in human anxiety.

According to clinialtrials. gov , there are currently no known clinical studies evaluating CCK antagonists for the treatment of anxiety disorders. Corticotropin-releasing factor CRF plays a role in stress response and individuals with anxiety disorders exhibit aberrant CRF homeostasis Conversely, CRF receptor antagonists have been shown to have potential anxiolytic effects in animal models The results from preliminary research in anxiety disorders, however, have been disappointing One randomized, double-blind trial of the CRF-1 antagonist, pexacerfont BMS , compared to escitalopram and placebo for the treatment of GAD, found that it did not separate from placebo There are also completed, but not published, studies for SAD comparing CRF-1 antagonists verucerfont GSK and emicerfont GW to alprazolam and placebo NCT , and a Phase 2 trial of patients with GAD comparing GW to paroxetine and placebo NCT Research on CRF-1 antagonists appears to have shifted toward addiction with recent trials of pexacerfont and verucerfont in alcohol use disorder , There are no known active trials of CRF-1 antagonists in anxiety disorders.

Orexin, also known as hypocretin, is a neuropeptide associated with arousal, appetite, and wakefulness Orexin is also thought to play a role in stress response with alterations in orexin found in depression and anxiety Based on the research finding that orexin levels are increased in CSF of individuals with PD , orexin is thought to have anxiogenic effects, leading to research on orexin-1 and orexin-2 receptor, and dual-receptor antagonists for treatment of anxiety disorders Suvorexant, an orexin-1 and orexin-2 receptor antagonist, is FDA-approved for primary insomnia, and is under study in PD, comparing the drug to placebo to monitor orexin levels and response to a carbon dioxide challenge NCT There are no other known ongoing studies of orexin antagonists in anxiety disorders.

In summary, neuropeptides appear to be a promising emerging field for the treatment of anxiety disorders but there no clear therapeutic candidates for anxiety disorder have been identified as of yet. Neurosteroids, also known as neuroactive steroids, act as transcription factors to regulate gene expression and endogenously modulate neuronal excitability by interacting with GABA-A, NMDA, and glutamate receptors Both preclinical and clinical studies have demonstrated evidence of aberrant neurosteroid homeostasis in anxiety disorders The antidepressant effects of SSRIs have been shown to correlate with increased brain and cerebrospinal fluid levels of allopregnanolone, a neurosteroid with potent modulatory activity on GABA-A receptors Because of their ability to rapidly control the excitability of the central nervous system, there has been increasing interest in the role of neurosteroids as novel treatments for anxiety disorders.

To date, two compounds with neurosteroidal activity, mifepristone RU and PH94B, have been investigated for the treatment of anxiety symptoms. RU is a progesterone inhibitor used for early pregnancy termination It is a glucocorticoid antagonist and has been studied for MDD with psychotic features, improving cognition in patients with bipolar disorder and schizophrenia, and for the treatment of PTSD.

A week, pilot clinical trial assessed the effect of mifepristone in older adults as a treatment for anxiety disorders with co-morbid cognitive dysfunction The study included 15 older adults ages 60 years and older with an anxiety disorder GAD, PD, or anxiety disorder not otherwise specified.

Subjects were randomized to either mifepristone mg daily or placebo for the first week of the study. After the first week, all patients received treatment with mifepristone mg daily for an additional 3 weeks. At the end of week 4, mifepristone was discontinued, and follow-up assessments of memory, executive function, and anxiety were completed at week Subjects with higher baseline cortisol levels had improvements in memory, executive function, and anxiety, while those with low or normal baseline cortisol levels experienced little to no mifepristone-related improvement.

There are no active studies of mifepristone in anxiety disorders. PH94B, an intranasally administered neurosteroidal aerosol, has been investigated for the acute treatment of SAD. In a phase 2, multi-center, randomized, double-blind, placebo-controlled, single-dose study, 91 females ages 19—60 years with SAD were randomized to receive either placebo or PH94B nasal spray 15 min prior to a public speaking or social interaction challenge under laboratory settings There were no differences in adverse events reported by the PH94B and placebo groups.

A second study assessed the use of PH94B for the treatment of symptoms of SAD in real-world settings in a pilot, randomized, double-blind, placebo-controlled trial Twenty-two males and females ages 18—65 years with SAD were randomized to either placebo or PH94 nasal spray.

The subjects were instructed to self-administer the nasal spray 15 min prior to a distressing social interaction or performance, up to four times per day.

PH94B was superior to placebo in decreasing mean peak levels of symptoms of social anxiety, as measured by subject-reported subjective units of distress SUDs.

The results of an open-label study of PH94B for the treatment of adjustment disorder with anxiety symptoms in adults which has planned to begin enrollment in will be of great interest NCT As noted above, clonidine may be used off-label for anxiety but there have been no recent clinical studies of clonidine in anxiety disorders.

There are no current drug trials of clonidine in PD, SAD, GAD, or SP. One RCT of guanfacine ER in children and adolescents ages 8—17 years with GAD, separation anxiety disorder, and SAD reported that the medication was safe and well-tolerated but it is unclear whether it is efficacious To date, there are also no known active studies of guanfacine in anxiety disorders.

As noted earlier, there is currently limited active investigation of propranolol for anxiety disorders outside of the extensive research done on memory consolidation and PTSD. In many parts of the world, cannabis is consumed for its euphoric and relaxing effects.

There is a widespread belief that cannabis, cannabidiol CBD , and other cannabinoids are harmless substances and can lower anxiety and induce relaxation. However, the literature does not support the belief that cannabinoids are safe for patients with anxiety disorders, nor does it support the notion that cannabinoids improve anxiety and related symptoms in those patients.

The quality of evidence currently available from clinical trials with cannabinoids and anxiety is very low.

This is in part because most of the studies included participants with a primary diagnosis of chronic non-cancer pain, multiple sclerosis or fibromyalgia, rather than anxiety disorders. Other limitations of these studies include small sample size and other methodological flaws Endogenous and exogenous cannabinoids act on the cannabinoid type 1 CB1 receptor, serotonergic type 1A 5HT 1A receptor and the transient receptor potential vanilloid type 1 TRPV1 receptor.

Cannabinoid type 1 receptor agonists have a biphasic effect: they have anxiolytic properties in low doses and anxiogenic properties in high doses.

While the activation of the CB1 receptor produces inhibitory effect in the neuron, leading to an anxiolytic effect, high doses of CB1 receptor agonists induce activation of TRPV1 receptor, which produces anxiogenic effects Several drugs that act as 5HT 1A receptor agonists proved to be effective in the treatment of anxiety disorders; recent studies indicate that cannabidiol and other cannabinoids also act on the 5HT 1A receptor, potentially resulting in anxiolytic effects The most studied cannabinoid in anxiety is CBD.

Preclinical animal model studies and human trials indicate that CBD is a potentially effective treatment for PD, GAD, and SAD In the study from Bergamaschi et al.

In another study, the same research team found that a single mg dose of CBD reduced the anxiety associated with a SPECT scan in patients with SAD Subjects received mg of CBD or placebo daily for 4 weeks.

The drug-placebo difference in LSAS was not statistically significant. Currently, there is a RCT with CBD underway NCT with an estimated completion date of October Excessive activity in limbic and paralimbic cortical areas has been consistently implicated in the pathophysiology of anxiety disorders.

The parahippocampal gyrus and hippocampus are thought to play a key role in mediating fear and anxiety. The public speaking test produces activation of limbic areas in SAD subjects, but in subjects treated with citalopram there is a decreased regional cerebral blood flow rCBF response in the amygdala, hippocampus, and the periamygdaloid, rhinal and parahippocampal cortices In the study from Crippa et al.

Although the effects of citalopram and CBD were similar in some areas, citalopram produced decreased rCBF in the cingulate gyrus, while CBD produced increased rCBF in the right posterior cingulate gyrus The anxiolytic effects observed with CBD are in contrast to the anxiogenic effects induced by deltatetrahydrocannabinol Deltatetrahydrocannabinol THC is a partial agonist of the CB1 receptor that can have anxiolytic effect in low doses, but in high doses can induce anxiety and panic attacks In a clinical trial for treatment of Tourette syndrome, the authors found worsening of obsessive-compulsive behavior after the administration of THC.

No significant differences were found in anxiety scores, but there was a trend of higher phobic anxiety after administration of THC There are no registered trials for THC in anxiety disorders. Dronabinol is a synthetic trans isomer of THC and, compared to THC has higher affinity to the CB1 receptor Two RCTs found that dronabinol was effective for treatment for pain, but neither study found significant changes in anxiety scores , In the study by Narang et al.

two subjects experienced high anxiety as a side effect of a higher dronabinol dose 20 mg There is one registered study listed as withdrawn NCT with dronabinol and anxiety disorders; there are no active studies. Nabilone is also a synthetic cannabinoid which is similar to but more potent than THC.

It has high affinity to CB1 and CB2 receptors. Four studies assessed the effects of nabilone in pain as a primary outcome and anxiety as a secondary outcome — One RCT which included subjects with neuropathic pain demonstrated that nabilone was effective for the treatment of pain but did not produce any changes in anxiety.

In the study by Toth et al. Skrabek et al. In patients with chronic headache, nabilone was more effective than ibuprofen for pain management, but there were no significant differences in anxiety scores Anxiolytic effects were observed only in a small portion of the patients.

Side effects included drowsiness, dry mouth, and dry eyes. Significant improvements in anxiety scores were also noted in a cross-over comparison of nabilone 1—2.

There are currently no registered clinical trials assessing nabilone in anxiety disorders. Preparations including both THC and CBD THC-CBD have been tested as treatments for pain in two RCTs. In two small RCTs which included patients with multiple sclerosis, THC-CBD did not increase or decrease anxiety , In one of those studies , THC-CBD was effective in the treatment of pain and sleep disturbances, while in the second study THC-CBD was not effective for pain.

In a RCT of THC-CBD for the treatment of Huntington's Disease , there were no significant improvements of motor, cognitive, behavioral, and functional scores.

Also, there were no significant changes in anxiety scores. There are no registered trials for THC-CBD in anxiety disorders, but there is one trial underway NCT assessing the effect of recreational cannabis use on anxiety symptoms. Regarding the safety of cannabinoids, currently there are no studies showing that CBD or nabilone increase anxiety or cause panic attacks, suggesting that these medications are safe for patients with anxiety disorders.

However, THC and dronabinol are likely not safe drugs for these patients because they can induce anxiety and panic attacks depending on the doses and individual predispositions of each patient. In conclusion, cannabidiol and nabilone are the most promising cannabinoids in the treatment of anxiety disorders, but the level of evidence for these drugs is still very low.

Overall, THC, THC-CBD and dronabinol seem to be ineffective and potentially harmful for subjects with anxiety disorders. There has been increased study of herbal medications for depression and anxiety, with over 30 medications having been tested in some capacity over the past 15 year Despite this burgeoning interest in natural agents, the data for most of them remains sparse.

The most widely studied herbal compound is kava, a plant containing kavapyrones, which are thought to exert anxiolytic effects through activity on sodium and calcium channels or most likely from action on GABA-A receptors like benzodiazepines A Cochrane meta-analysis of RCTs of kava in anxiety disorders, published in , reported reductions in anxiety scores and separation from placebo A more recent analysis was more conservative and noted that kava could be recommended for short-term use in anxiety but should not replace longer-term medications , while another review concluded that, given insufficient evidence, kava could not be recommended for GAD All the above reviews also noted the risk of liver toxicity, including potentially severe liver toxicity, with the use of kava.

There are no known active or upcoming studies of kava in anxiety disorders. Several systematic reviews of other herbal compounds for the treatment of anxiety and anxiety disorders have been conducted and reported including RCTs for several agents such as ashwagandha, passionflower, galphimia, echinacea, ginkgo, chamomile, lemon balm, valerian, and lavender , , A recent trial compared Galphimine-B G-B , isolated from Galphimia and found in rats to have anxiolytic effect through inhibition of dopaminergic neurons in the ventral tegmental area , to alprazolam, a benzodiazepine, as a control, in patients with GAD and reported that G-B had comparable efficacy to alprazolam with less sedation Although there have been several positive studies of natural treatments for GAD, in particular for chamomile , the agent with strongest evidence for use is kava.

Currently, there are ongoing clinical trials using lavender thought to treat anxiety by inhibiting voltage-gated calcium channels for dental NCT and pre-operative anxiety NCT and a Phase 2 randomized double-blind trial comparing galphimia to alprazolam for the treatment of anxiety NCT Although saffron Crocus sativus has been studied for depression and anxiety, due to its possible effects of inhibiting serotonin reuptake in synapses , there is only one listed study, a randomized, double-blind RCT in mild to moderate GAD, although its status is unknown NCT Since this group's last review of novel therapies for anxiety disorders in , there has been little headway made in the development or clinical evaluation of new drugs for PD, GAD, and SAD.

There have been no new medications approved by the FDA for any anxiety disorder during that time. Although there have been trials of serotonergic agents like vortioxetine and agomelatine , glutamate modulators such as riluzole and ketamine , neuropeptides, and even cannabinoids, very few have advanced to Phase III trials or have shown real promise for anxiety disorders.

Moreover, the field lacks data contrasting specific drugs or mechanisms of action with efficacy, which would be required to propose rational protocols for the selection of optimally efficacious treatments.

The traditional areas of research for anxiety included serotonin, norepinephrine, and GABA, and indeed there are several drugs recently studied and under investigation targeting these neurotransmitters. This research, however, has been built upon the previous success of SSRIs, SNRIs, and GABAergic agents like benzodiazepines, and, to a lesser extent, pregabalin and gabapentin, neither of which are approved in the United States but are prescribed off-label for anxiety.

The temptation to continue work on these pathways is due to the acknowledgment that these treatments are effective while failing to expand beyond this comfort zone.

Indeed, the neurobiology of anxiety has expanded well beyond the research on fear condition, false suffocation alarms, and the neuroendocrine and HPA-axis models of panic and fear. The early neurocircuitry models of anxiety were based on pre-clinical research and cast a wide net, including PTSD in those models.

It is now better understood how much heterogeneity exists between PTSD and other anxiety disorders and even in the class of anxiety disorders, among PD, SAD, and GAD While neuroimaging studies in the last two decades have led to a refined understanding of brain circuits involved in fear and anxiety, this knowledge has not yet translated in insights leading to novel treatments with the exception, perhaps, of attempts to use transcranial magnetic stimulation to modulate anxiety and fear circuitry This is also because in general pharmacotherapies are less clearly related to the functioning of specific brain circuits.

The pursuit of novel pharmacotherapies for anxiety disorders has been fraught with many complications. The first-line treatments, SSRIs and SNRIs, were originally approved for depressive disorders and then later for anxiety disorders.

There have been very few drugs developed de novo for anxiety. Studies of newer agents have been hampered by flawed study designs such as lack of controls or using placebos instead of comparison to established medications such as SSRIs or benzodiazepines. While this may seem like an insurmountable hurdle, there is hope in that several compounds, including neurosteroids, neuropeptides, and phytochemicals herbal compounds , have shown some potential.

It also would help to study medications specifically for how the disorder manifests clinically, such as how PH94B has been investigated for performance anxiety in SAD by being administered 15 min before the participant is to have a social interaction or give a performance Therein lies a second area of concern.

Although it has been assumed that most patients respond to SSRI or SNRI medications, benzodiazepines, psychological treatments, or some combination, about one-third of these patients have treatment-refractory anxiety. There is still little known about treatment resistance in anxiety disorders and how to treat it effectively.

It also remains unclear how many patients are being treated with effective doses or being given adequate trials or are potentially being misdiagnosed or treated with inappropriate regimens. Anxiety disorders, in addition to their high prevalence, are a leading cause of disability, which is exacerbated by their high comorbidity with depression Naturalistic studies may be needed to understand how to treat anxiety patients with psychiatric, medical, and substance comorbidities.

Perhaps the clearest limitation of this synopsis is the intentional omission of psychotherapies for anxiety disorders. Although their efficacy in PD, GAD, and SAD, has been documented, this review aimed to focus on pharmacotherapies.

That said, it is impossible to ignore the importance of therapy-assisted medications such as DCS or potentially even psychedelic medications.

Ideally, such medications could reduce the distress related to exposure techniques and enhance the retention of information in anxiety-focused psychotherapy, ultimately increasing its overall efficacy. Such medications are also important given the lack of access to care and how few patients are in fact being treated first by psychiatrists for medication management and can receive appropriate CBT or exposure therapies for their anxiety disorders.

This is certainly an area that needs greater investigation. Further research on augmented psychotherapies should not, however, preclude the concomitant development of novel pharmacotherapies, especially given evidence for greater efficacy of pharmacologic treatments over psychological therapies for certain anxiety disorders such as GAD Since this review did not uncover a wide range of support for promising pharmacotherapies for anxiety disorders in development, we need to reconsider what treatments currently work best, and what areas to focus on going forward.

While developing serotonergic or GABAergic agents with more favorable side effect profiles compared to SSRIs, SNRIs, and benzodiazepines, gabapentin and pregabalin may have some clinical value, there needs to be further expansion into agents targeting neuropeptide pathways, glutamate, endocannabinoids, and multi-modal medications including phytochemicals and hallucinogens.

These newer compounds may not replace the current treatments but may over time serve as adjuncts or aid in therapy, at least until the field can develop better biomarkers and incorporate brain imaging, pharmacogenomic and other neurobiochemical advances.

In terms of pharmacological development, it is time for anxiety disorders to catch up to depression, PTSD, bipolar disorder, and schizophrenia.

AG, JM, RT, RF, and DI contributed to conception and design and wrote the original draft of the manuscript. AG, JM, RF, RT, KL, FB, and DI contributed to manuscript revisions, review and analysis of the literature, and creation of the tables. All authors reviewed and approved the final draft of the manuscript and made substantial contributions to this study.

JM is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders and on a patent pending for the use of ezogabine and other KCNQ channel openers to treat depression and related conditions.

The Icahn School of Medicine employer of JM is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine or esketamine for the treatment of depression. The Icahn School of Medicine is also named on a patent related to the use of ketamine for the treatment of PTSD.

JM is not named on these patents and will not receive any payments. In the last 5 years, DI has received consulting honoraria from Alkermes, Axsome, Centers for Psychiatric Excellence, Jazz, Lundbeck, Otsuka, Precision Neuroscience, Sage, Sunovion; he has received research support through his academic institution from Alkermes, Astra Zeneca, Brainsway, Litecure, Neosync, Otsuka, Roche, Shire.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE.

Prevalence, severity, and comorbidity of month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. doi: CrossRef Full Text Google Scholar. Depression and Other Common Mental Disorders: Global Health Estimates.

Geneva: World Health Organization Ahola K, Virtanen M, Honkonen T, Isometsä E, Aromaa A, Lönnqvist J. Common mental disorders and subsequent work disability: a population-based health study.

J Affect Disord. PubMed Abstract CrossRef Full Text Google Scholar. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ. PubMed Abstract Google Scholar.

Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders ESEMeD project.

Acta Psychiatr Scand Suppl. CrossRef Full Text. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry.

Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, Spencer MA, Culpepper L, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients.

J Nerv Ment Dis. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a year prospective study.

Am J Psychiatry. Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC Google Scholar. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, et al. Analysis of shared heritability in common disorders of the brain. Sartori SB, Singewald N.

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther.

Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. Practice Guideline for the Treatment of Patients with Panic Disorder. National Institute for Health and Care Excellence NICE. Generalised Anxiety Disorder and Panic Disordr in Adults: Management.

Social Anxiety Disorder: Recognition, Assessment and Treatment. He H, Xiang Y, Gao F, Bai L, Gao F, Fan Y, et al. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis.

J Psychiatr Res. Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry. Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, et al.

Br J Psychiatry. Bakker A, Van Balkom A, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. Curtiss J, Andrews L, Davis M, Smits J, Hofmann SG. A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators.

Expert Opin Pharmacother. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. Imai H, Tajika A, Chen P, Pompoli A, Guaiana G, Castellazzi M, et al. Azapirones versus placebo for panic disorder in adults.

Rissardo JP, Caprara ALF. Buspirone-associated movement disorder: a literature review. Prague Med Rep. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.

J Clin Psychopharmacol. Moll JL, Brown CS. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. J Sexual Med. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders.

CNS Drugs. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder.

Braz J Med Biol Res. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study.

Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, et al.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, et al.

Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.

Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety anxious depression : a pooled analysis of 10 studies.

Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.

Psychopharmacol Bull. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant bupropion in the treatment of panic disorder with phobias.

Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, et al. Bupropion sustained release for panic disorder. Papp LA, Coplan JD, Martinez JM, de Jesus M, Gorman JM.

Efficacy of open-label nefazodone treatment in patients with panic disorder. Bystritsky A, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder. Depress Anxiety. DeMartinis NA, Schweizer E, Rickels K.

An open-label trial of nefazodone in high comorbidity panic disorder. Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, et al.

Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Agarwal SD, Landon BE.

Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. Torres-Bondia F, de Batlle J, Galván L, Buti M, Barbé F, Piñol-Ripoll G. Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from to BMC Public Health.

Balon R, Starcevic V. Role of benzodiazepines in anxiety disorders. Adv Exp Med Biol. Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? Gomez AF, Barthel AL, Hofmann SG.

Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Offidani E, Guidi J, Tomba E, Fava GA.

Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis.

Osler M, Jørgensen MB. Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. Lim B, Sproule BA, Zahra Z, Sunderji N, Kennedy SH, Rizvi SJ.

Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.

Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis.

Kawalec P, Cierniak A, Pilc A, Nowak G. Pregabalin for the treatment of social anxiety disorder. Expert Opin Investig Drugs. Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled week study.

Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.

Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.

Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System FAERS.

Res Social Adm Pharm. Schifano F, Chiappini S. Pregabalin: a range of misuse-related unanswered questions. CNS Neurosci Ther. Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study.

J Anal Toxicol. Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, et al. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review. Prim Care Companion CNS Disord.

Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, et al. Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review. Front Psychiatry. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder.

de-Paris F, Sant'Anna MK, Vianna MR, Barichello T, Busnello JV, Kapczinski F, et al. Effects of gabapentin on anxiety induced by simulated public speaking.

J Psychopharmacol. PubMed Abstract CrossRef Full Text. Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review.

Schmitt U, Lüddens H, Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm. Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.

Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Möller HJ, Padberg F, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.

Urbano MR, Spiegel DR, Laguerta N, Shrader CJ, Rowe DF, Hategan LF. Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults. Prim Care Companion J Clin Psychiatry. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR.

Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Masdrakis VG, Papadimitriou GN, Oulis P.

Lamotrigine administration in panic disorder with agoraphobia. Clin Neuropharmacol. Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Aliyev NA, Aliyev ZN.

Valproate depakine-chrono in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study.

Eur Psychiatry. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, et al.

Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study.

Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. Davidson JR.

Pharmacotherapy of social anxiety disorder: what does the evidence tell us? Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder.

Strawn JR, Compton SN, Robertson B, Albano AM, Hamdani M, Rynn MA. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial.

J Child Adolesc Psychopharmacol. Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, et al. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK.

Effects of clonidine on anxiety disorders. Bergendahl H, Lönnqvist PA, Eksborg S. Clonidine in paediatric anaesthesia: review of the literature and comparison with benzodiazepines for premedication. Acta Anaesthesiol Scand. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al.

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. Perna G, Alessandra A, Raffaele B, Elisa M, Giuseppina D, Paolo C, et al. Is there room for second-generation antipsychotics in the pharmacotherapy of panic disorder?

A systematic review based on PRISMA guidelines. Int J Mol Sci. Griebel G, Holmes A. Nat Rev Drug Discov. Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis.

Asian J Psychiatr. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.

Schneier FR, Moskow DM, Choo TH, Galfalvy H, Campeas R, Sanchez-Lacay A. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder.

Careri JM, Draine AE, Hanover R, Liebowitz MR. A week doubleblind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Clayton AH, Durgam S, Tang X, Chen C, Ruth A, Gommoll C. Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies.

Neuropsychiatr Dis Treat. Yee A, Ng CG, Seng LH. Vortioxetine treatment for anxiety disorder: a meta-analysis study. Curr Drug Targets. Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine Lu AA in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

Eur Neuropsychopharmacol. Baldwin DS, Loft H, Florea I. Lu AA, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.

Qin B, Huang G, Yang Q, Zhao M, Chen H, Gao W, et al. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. BMJ Open. Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.

Ann Genrl Psychiatry. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT 1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. Pecknold JC, Luthe L, Scott-Fleury MH, Jenkins S.

Gepirone and the treatment of panic disorder: an open study. Kaur Gill A, Bansal Y, Bhandari R, Kaur S, Kaur J, Singh R, et al. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties. Drugs Today.

Fabre-Kramer Pharmaceuticals I. Nishitsuji K, To H, Murakami Y, Kodama K, Kobayashi D, Yamada T, et al. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial. Clin Drug Investig. Lin J, Su Y, Wang C, Yang F, Xu Y, Yuan Y, et al.

Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, open-label study. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, et al.

Effects of PRX, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. Wesołowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB after intrahippocampal administration to rats.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy. Why UpToDate? Product Editorial Subscription Options Subscribe Sign in. View Topic Loading Font Size Small Normal Large. Generalized anxiety disorder in adults: Management. Formulary drug information for this topic. No drug references linked in this topic.

Find in topic Formulary Print Share. Official reprint from UpToDate ® www. com © UpToDate, Inc. All Rights Reserved. Authors: Michelle Craske, PhD Alexander Bystritsky, MD, PhD Section Editor: Murray B Stein, MD, MPH Deputy Editor: Michael Friedman, MD.

All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan This topic last updated: Jul 05, Suboptimal response Adjunctive CBT — For individuals with suboptimal response eg, partial or no response to initial pharmacologic management, we suggest adjunctive cognitive-behavioral therapy CBT.

Pharmacologic management No response to SRI treatment — For individuals who are unresponsive to the initial serotonergic reuptake inhibitor SRI agent in addition to adjunctive CBT, we suggest tapering off of the first agent and titrating another SRI.

Unresponsive to multiple agents Choice of medication — In our clinical experience, a substantial proportion of patients with GAD do not improve or have residual symptoms despite multiple trials of medications and augmenting agents [ 17,35 ]. DURATION OF TREATMENT Pharmacotherapy — If effective, antidepressant treatment for generalized anxiety disorder GAD should be continued for at least 12 months [ 73,74 ].

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM-5 , American Psychiatric Association, Arlington, VA Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol ; Kessler RC, McGonagle KA, Zhao S, et al.

Lifetime and month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Arch Gen Psychiatry ; Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a year prospective study.

Am J Psychiatry ; Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry ; 63 Suppl Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of month DSM-IV disorders in the National Comorbidity Survey Replication.

Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther ; Stein MB, Sareen J.

CLINICAL PRACTICE. Generalized Anxiety Disorder. N Engl J Med ; Weissman MM, Verdeli H, Gameroff MJ, et al. National survey of psychotherapy training in psychiatry, psychology, and social work. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.

Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder.

Cochrane Database Syst Rev ; :CD Hendriks GJ, Oude Voshaar RC, Keijsers GP, et al. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand ; Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy.

Psychol Bull ; Carl E, Witcraft SM, Kauffman BY, et al. Psychological and pharmacological treatments for generalized anxiety disorder GAD : a meta-analysis of randomized controlled trials. Cogn Behav Ther ; Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.

Lancet ; Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol ; Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.

J Clin Psychiatry ; Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Dahl AA, Ravindran A, Allgulander C, et al. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.

Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety ; Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Davidson JR, Bose A, Wang Q.

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.

J Affect Disord ; Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis ; Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials.

Hall J, Kellett S, Berrios R, et al. Efficacy of Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults: Systematic Review, Meta-Analysis, and Meta-Regression. Am J Geriatr Psychiatry ; Brenes GA, Danhauer SC, Lyles MF, et al.

Telephone-Delivered Cognitive Behavioral Therapy and Telephone-Delivered Nondirective Supportive Therapy for Rural Older Adults With Generalized Anxiety Disorder: A Randomized Clinical Trial.

JAMA Psychiatry ; Loerinc AG, Meuret AE, Twohig MP, et al. Response rates for CBT for anxiety disorders: Need for standardized criteria. Clin Psychol Rev ; Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.

Ann Clin Psychiatry ; Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol ; Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.

Lydiard RB. An overview of generalized anxiety disorder: disease state--appropriate therapy. Clin Ther ; 22 Suppl A:A3. Allgulander C, Bandelow B, Hollander E, et al.

WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr ; Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol ; Allgulander C, Hackett D, Salinas E.

Venlafaxine extended release ER in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry ; Carter NJ, McCormack PL.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs ; Carter CS, Krug MK. The functional neuroanatomy of dread: Functional magnetic resonance imaging insights into generalized anxiety disorder and its treatment.

Li X, Zhu L, Zhou C, et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.

PLoS One ; e He H, Xiang Y, Gao F, et al. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. J Psychiatr Res ; Stahl SM, Ahmed S, Haudiquet V.

Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Wetherell JL, Petkus AJ, White KS, et al.

Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Crits-Christoph P, Newman MG, Rickels K, et al. Combined medication and cognitive therapy for generalized anxiety disorder.

J Anxiety Disord ; Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Delle Chiaie R, Pancheri P, Casacchia M, et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.

J Clin Psychopharmacol ; Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry ; Garakani A, Freire RC, Murrough JW.

Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls. Ahmed S, Bachu R, Kotapati P, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.

Masdrakis VG, Papadimitriou GN, Oulis P. Lamotrigine administration in panic disorder with agoraphobia. Clin Neuropharmacol ; Schatzberg AF. New indications for antidepressants. J Clin Psychiatry ; 61 Suppl Huh J, Goebert D, Takeshita J, et al.

Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord ; Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.

Core Evid ; Gommoll C, Durgam S, Mathews M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. Kreys TJ, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy ; Gao K, Muzina D, Gajwani P, Calabrese JR.

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. Charney DS, Minic SJ, Harris RA. Hypnotics and sedatives. In: Goodman and Gilman's: The pharmacological basis of therapeutics, 10th ed, Hardman JG, Limbird LE Eds , McGraw-Hill, New York Chouinard G, Lefko-Singh K, Teboul E.

Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol ; Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis.

Psychother Psychosom ; Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA ; Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder.

J Clin Psychiatry ; 70 Suppl Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry ; 62 Suppl Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother ; Hackett D, Haudiquet V, Salinas E.

A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry ; Rickels K, Lucki I, Schweizer E, et al. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation.

Plag J, Schmidt-Hellinger P, Klippstein T, et al. Working out the worries: A randomized controlled trial of high intensity interval training in generalized anxiety disorder.

Simon NM, Hofmann SG, Rosenfield D, et al. Efficacy of Yoga vs Cognitive Behavioral Therapy vs Stress Education for the Treatment of Generalized Anxiety Disorder: A Randomized Clinical Trial. Hoge EA, Bui E, Marques L, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity.

Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Rickels K, Etemad B, Khalid-Khan S, et al.

Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Craske MG, Roy-Byrne P, Stein MB, et al. CBT intensity and outcome for panic disorder in a primary care setting.

Behav Ther ; It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances.

Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications.

This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. All rights reserved. GRAPHICS Side effects of antidepressant medications [].

Refer to "Anticholinergic" data column for frequency rankings. References: Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int ; Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis.

Drug Saf ; Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Lexicomp Online. Copyright © Lexicomp, Inc. Baldwin DS, Chrones L, Florea I, et al.

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5 th ed, Schatzberg AF, Nemeroff CB Eds , American Psychiatric Association Publishing Pharmacology of medicines for treatment of adults with generalized anxiety disorder GAD.

Adverse effects of individual agents are presented in a separate table in UpToDate. The pharmacology of benzodiazepines used for treatment of adults with generalized anxiety disorder is presented in a separate table in UpToDate.

GAD: generalized anxiety disorder; SSRI: selective serotonin reuptake inhibitor; CYP: cytochrome P; SNRI: serotonin-norepinephrine reuptake inhibitor; GABA: gamma aminobutyric acid; SGA: second-generation antipsychotic. Only strong or moderate effects on other drugs are listed.

These classifications are based upon US Food and Drug Administration guidance. Other sources may use a different classification system resulting in some agents being classified differently.

Specific drug interactions and management suggestions may be determined by use of Lexi-Interact , the drug interactions program included with UpToDate. Prepared with data from: World Federation of Societies of Biological Psychiatry WFSBP , "Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, First Revision," World J Biol Psychiatry.

Bandelow B, Sher L, Bunevicius R, et al.

Selective serotonin anxietty inhibitors, Generalied reuptake inhibitors, and benzodiazepines generapized the Creatine and depression common medications for anxiety and generalizec. Anxiety disorders Antidepressant for generalized anxiety disorder the most common type of mental health condition in the United States, affecting 40 million adults yearly. This article will discuss medications a doctor may prescribe to treat anxiety and depression. It will also explore other treatment options and diagnostic processes for these conditions. Anxiety and depression are mental health conditions. Anxiety links closely with fear.